anti-CD19 CAR-T + anti-CD22 CAR-T

anti-CD19 CAR-T + anti-CD22 CAR-T is a dual-targeted chimeric antigen receptor T-cell therapy in which a patient's own T cells are genetically engineered ex vivo to express synthetic receptors targeting both CD19 and CD22, surface antigens found on B-cell malignancies. These engineered T cells are expanded and infused back into the patient as a living cell therapy. By targeting both antigens, this approach addresses a major limitation of single-target CAR-T (antigen escape) and aims to prevent relapse due to loss or downregulation of either antigen. The therapy has shown high rates of complete remission and measurable residual disease (MRD) negativity in patients with relapsed/refractory acute lymphoblastic leukemia and other B-cell hematologic cancers. Key advantages include higher partial response rate and lower neurotoxicity (ICANS) compared to single-target or CD19/CD20 CAR-T products. The mechanism involves T-cell mediated cytotoxicity against B-lineage cancer cells expressing CD19 and/or CD22. Development is ongoing, with multiple clinical trials in relapsed/refractory B-ALL and other blood cancers.

Other names

dual-targeted CD19/CD22 CAR-Tcotransduced CD19/CD22 CAR-TCD19/CD22 dual CAR-T